A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer

NCT00383149 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

58

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG: Ixabepilone
DRUG: Cetuximab

Sponsor

R-Pharm